NEW YORK, November 18, 2016 /PRNewswire/ --
On Thursday, major US indices were back in full swing into bullish territories
Berkeley, California headquartered Dynavax Technologies Corp.'s stock finished Thursday's session 2.17% lower at $4.50 with a total volume of 2.10 million shares traded. Shares of the Company, which discovers and develops novel vaccines and therapeutics in the US, are trading below its 50-day and 200-day moving averages by 57.00% and 70.47%, respectively. Dynavax Technologies' stock has a Relative Strength Index (RSI) of 27.00. Free research report on DVAX is available at:
On Thursday, shares in Edison, New Jersey headquartered ContraVir Pharmaceuticals Inc. ended the session 0.50% lower at $2.01 with a total volume of 286,414 shares traded. ContraVir Pharma's shares have surged 71.79% in the previous three months and 24.84% in the past one year. The stock is trading 29.14% above its 50-day moving average and 71.01% above its 200-day moving average. Moreover, shares of the Company, which operates as a biopharmaceutical company focused on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections, have an RSI of 57.49. The complimentary research report on CTRV can be downloaded at:
On Thursday, shares in Berkeley, California headquartered XOMA Corp. recorded a trading volume of 32,059 shares. The stock ended the day 3.73% lower at $6.97. XOMA's stock has surged 31.26% in the past one month. The Company is trading below its 50-day and 200-day moving averages by 15.03% and 44.30%, respectively. Furthermore, shares of XOMA, which discovers, develops, and commercializes antibody-based therapeutics in the US, Europe, and the Asia/Pacific, have an RSI of 54.61.
On November 14th, 2016, research firm Wedbush downgraded the Company's stock rating from 'Outperform' to 'Neutral'. The research firm also revised downwards its previous target price from $17 to $14. Visit us today and access our complete research report on XOMA at:
Cambridge, Massachusetts-based Agios Pharmaceuticals Inc.'s stock advanced 1.40%, to close the day at $62.81. The stock recorded a trading volume of 513,509 shares. Agios Pharma's shares have surged 29.99% in the last one month and 57.42% in the previous three months. Shares of the Company, which engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the US, are trading 21.61% and 36.45% above its 50-day and 200-day moving averages, respectively. Additionally, the stock has an RSI of 65.33.
On October 24th, 2016, research firm Needham initiated a 'Buy' rating on the Company's stock, issuing a target price of $60 per share. Get free access to your research report on AGIO at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...
Hashimoto's thyroiditis is an autoimmune disorder of the thyroid causing hypothyroidism. Synthetic ...
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...View All